



Madrid, June 12, 2025

Making Science Group, S.A. (hereinafter "Making Science", "Making Science Group", the "Company", or the "Group"), pursuant to the provisions of Article 17 of Regulation (EU) No. 596/2014 on market abuse, Article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services, and concordant provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity (hereinafter "BME Growth"), hereby brings to your attention the following:

OTHER RELEVANT INFORMATION

In Madrid, on June 12, 2025, at 9:00 a.m., an Ordinary General Shareholders' Meeting of the Company was held at the Company's registered office, with 70.2% of the Company's share capital with voting rights in attendance. At said meeting, the items on the agenda of the call published on the BME Growth website as "other relevant information" on May 9, 2025, as well as on the website on the same date, were submitted for deliberation by the attendees, and the following resolutions were unanimously adopted by the attendees:

FIRST. Examination and approval, as the case may be, of the Annual Accounts of the Company, comprising the Balance Sheet, the Profit and Loss Account, the Statement of Changes in Net Equity, the Cash Flow Statement and the Annual Report, as well as the Management Report for the fiscal year ended December 31, 2024.

SECOND: Examination and approval, as the case may be, of the proposed distribution of the profit for the year ended December 31, 2024.

Basis of distribution

Profit and loss (gain) +22,031,556 euros.

Application:

To legal reserve 2,497 euros

To voluntary reserves 19,730,718 euros

To prior years' losses 2,298,341 euros

Total 22,031,556 euros

THIRD: Examination and approval, as the case may be, of the consolidated Annual Accounts of the Group, comprising the consolidated Balance Sheet, consolidated Profit

and Loss Account, consolidated Statement of Changes in Net Equity, consolidated Cash Flow Statement and consolidated Annual Report, as well as the Management Report for the fiscal year ended December 31, 2024.

FOURTH: Examination and approval, as the case may be, of the statement of non-financial information for fiscal year 2024.

FIFTH. Examination and approval, if applicable, of the management of the Board of Directors during the fiscal year ended December 31, 2024.

SIXTH. Re-election of Grant Thornton, S.L.P., a sole proprietorship, as Auditor of the Company's accounts and of the consolidated accounts of the Group, for the fiscal year ending on December 31, 2025.

SEVENTH. Approval, if applicable, of the remuneration policy for the Board and executive directors for the year 2025.

In accordance with the provisions of Article 17 of the Company's Bylaws, a maximum annual remuneration of 1,300,000 euros is approved for the directors of the Company for the year ending December 31, 2025.

EIGHTH. Delegation of powers.

NINTH: Drafting, reading and approval, if applicable, of the minutes of the meeting.

In compliance with the provisions of BME MTF Equity Circular 3/2020, it is hereby expressly stated that the information provided herein has been prepared under the sole responsibility of the Company and its directors in their current position.

Sincerely yours,

José Antonio Martínez Aguilar
Chief Executive Officer of Making Science Group, S.A.